Medy Tox Revenue vs. Operating Margin

086900 Stock  KRW 131,400  1,800  1.35%   
Based on the key profitability measurements obtained from Medy Tox's financial statements, Medy Tox may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Medy Tox's ability to earn profits and add value for shareholders.
For Medy Tox profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Medy Tox to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Medy Tox utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Medy Tox's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Medy Tox over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Medy Tox's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medy Tox is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medy Tox's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Medy Tox Operating Margin vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Medy Tox's current stock value. Our valuation model uses many indicators to compare Medy Tox value to that of its competitors to determine the firm's financial worth.
Medy Tox is rated second in revenue category among its peers. It also is rated second in operating margin category among its peers . The ratio of Revenue to Operating Margin for Medy Tox is about  1,137,658,756,677 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Medy Tox by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Medy Tox's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Medy Revenue vs. Competition

Medy Tox is rated second in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 430.02 Billion. Medy Tox totals roughly 184.87 Billion in revenue claiming about 43% of equities under Health Care industry.

Medy Operating Margin vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Medy Tox

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
184.87 B
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Medy Tox

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
0.16 %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.

Medy Tox Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Medy Tox, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Medy Tox will eventually generate negative long term returns. The profitability progress is the general direction of Medy Tox's change in net profit over the period of time. It can combine multiple indicators of Medy Tox, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Medy-Tox Inc., a biopharmaceutical company, develops, manufactures, markets, and sells botulinum toxin and hyaluronic acid dermal filler products primarily in South Korea. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea. MedyTox is traded on Korean Securities Dealers Automated Quotations in South Korea.

Medy Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Medy Tox. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Medy Tox position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Medy Tox's important profitability drivers and their relationship over time.

Use Medy Tox in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medy Tox position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medy Tox will appreciate offsetting losses from the drop in the long position's value.

Medy Tox Pair Trading

Medy Tox Pair Trading Analysis

The ability to find closely correlated positions to Medy Tox could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medy Tox when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medy Tox - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medy Tox to buy it.
The correlation of Medy Tox is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medy Tox moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medy Tox moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medy Tox can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Medy Tox position

In addition to having Medy Tox in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Cap ETFs Thematic Idea Now

Small Cap ETFs
Small Cap ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small Cap ETFs theme has 167 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Cap ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Medy Stock

To fully project Medy Tox's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Medy Tox at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Medy Tox's income statement, its balance sheet, and the statement of cash flows.
Potential Medy Tox investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Medy Tox investors may work on each financial statement separately, they are all related. The changes in Medy Tox's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Medy Tox's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.